Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective May 19, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.177, Imetelstat (Rytelo™)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

May 19, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new Medicare Advantage policy MA08.177 has been created for Imetelstat (Rytelo™), a new pharmacy benefit. This policy will establish coverage guidelines and billing requirements for this medication starting May 19, 2025.

Action Required

Action needed

By May 19, 2025: Billing team should review the full policy MA08.177 for Imetelstat (Rytelo™) to understand coverage criteria, prior authorization requirements, and billing procedures for Medicare Advantage plans. Monitor for additional guidance on specific HCPCS codes and documentation requirements.

Related policy hubs

Independence Blue Cross policies Oncology Hematology